Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.74 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy?
Dianthus Therapeutics, Inc. (DNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.51 per share a year ago.
Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline
Dianthus Therapeutics, Inc. (DNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.54 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.71 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $3.78 per share a year ago.
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.80 per share a year ago.
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
Research Analysts Offer Predictions for Dianthus Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:DNTH)
Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – HC Wainwright issued their Q2 2024 EPS estimates for Dianthus Therapeutics in a note issued to investors on Thursday, May 16th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.28) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.16) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q3 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.65) EPS, Q1 2025 earnings at ($0.65) EPS, Q2 2025 earnings at ($0.75) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.70) EPS, FY2025 earnings at ($2.79) EPS, FY2026 earnings at ($3.82) EPS, FY2027 earnings at ($4.30) EPS and FY2028 earnings at ($3.26) EPS. Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.11) by $0.40. The firm had revenue of $0.46 million during the quarter, compared to analysts’ expectations of $0.73 million. Several other equities research analysts also recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Dianthus Therapeutics in a research note on Thursday, February 15th. They set a “buy” rating and a $44.00 price objective for the company. Jefferies Financial Group lifted their price objective on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Raymond James lifted their price objective on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, April 18th. Finally, Wedbush boosted their target price on shares of Dianthus Therapeutics from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Friday, May 10th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $42.83. Get Our Latest Report on Dianthus Therapeutics Dianthus Therapeutics Trading Down 2.4 % NASDAQ DNTH opened at $25.63 on Monday. The firm’s fifty day simple moving average is $25.63 and its two-hundred day simple moving average is $18.97. Dianthus Therapeutics has a 12-month low of $6.58 and a 12-month high of $33.77. The firm has a market capitalization of $752.21 million, a P/E ratio of -4.40 and a beta of 1.77. Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC purchased a new position in Dianthus Therapeutics in the fourth quarter valued at $25,000. Citigroup Inc. purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $53,000. Hussman Strategic Advisors Inc. purchased a new stake in shares of Dianthus Therapeutics during the first quarter worth about $630,000. Acadian Asset Management LLC purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $303,000. Finally, Laurion Capital Management LP purchased a new stake in shares of Dianthus Therapeutics during the third quarter worth about $497,000. Hedge funds and other institutional investors own 47.53% of the company’s stock. Dianthus Therapeutics Company Profile (Get Free Report) Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. See Also Five stocks we like better than Dianthus Therapeutics Retail Stocks Investing, Explained MarketBeat Week in Review – 5/13 – 5/17 Why Invest in Biotech Stocks Take-Two Interactive Software Offers 2nd Chance for Investors 3 Grocery Stocks That Can Help Take a Bite Out of Inflation Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
